Klinische Studie

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

NCT: NCT03223103 · ACTIVE_NOT_RECRUITING

NCT-IDNCT03223103

Medizinische Daten: StatusACTIVE_NOT_RECRUITING

Startdatum2018-03-01

Abschluss2029-05-12

SponsorAdilia Hormigo (OTHER)

First posted2017-07-19

Last updated2026-09-21

Kurzzusammenfassung

The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields). The study is designed to determine whether this treatment combination is well tolerated and safe.

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.